Acorda Launches Art Initiative to Foster Better Conversations About Parkinson’s Symptoms

Date : 12/05/2018 @ 12:00PM
Source : Business Wire
Stock : Acorda Therapeutics, Inc. (ACOR)
Quote : 15.85  -0.31 (-1.92%) @ 4:31PM

Acorda Launches Art Initiative to Foster Better Conversations About Parkinson’s Symptoms

Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Historical Stock Chart

1 Month : From Nov 2018 to Dec 2018

Click Here for more Acorda Therapeutics, Inc. Charts.

Framing OFF Through Art℠ Uses the Power of Art to Illustrate the Impact of OFF Periods

Acorda Therapeutics, Inc. (Nasdaq:ACOR) today launched Framing OFF Through Art℠, a new initiative that uses the power of art to allow people with Parkinson’s to help recognize and articulate their OFF period experiences. This initiative builds on Acorda’s “Live Well. Do Tell.℠” program, which was launched in March 2018.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181205005342/en/

Steve and Leslie Peters, Dr. Matthew Stern and Julie B. examine the art. Dr. Stern, a movement disorder specialist, which is a neurologist who has received additional training in Parkinson's and other movement disorders, provided additional insight into the symptoms of OFF periods. (Photo: Business Wire)

Many people with Parkinson’s experience OFF periods in which Parkinson’s symptoms re-emerge even though the person is on an existing treatment regimen. OFF periods affect about 40 percent of the approximately one million people with Parkinson’s in the U.S. The need for better dialogue about OFF period symptoms was originally highlighted in the “Live Well. Do Tell.” Statement of Need, a report developed based on insights from a multi-disciplinary steering committee of Parkinson’s community leaders.

Framing OFF Through Art includes a series of artworks inspired by the personal stories of people with Parkinson’s and their care partners. The artworks were created by artists who have personal connections to the disease. Each artist partnered with two people with Parkinson’s and their care partners and developed a work of art to represent their stories. The art is intended to educate and encourage other people with Parkinson’s and their care partners to recognize OFF period symptoms and start a conversation with their own healthcare teams.

“OFF periods can be frustrating and challenging, as symptoms are varied and often difficult for patients to communicate effectively to their care providers,” said Matthew Stern, M.D., Director Emeritus of the Parkinson's Disease and Movement Disorders Center, Department of Neurology, University of Pennsylvania Health System, Pennsylvania Hospital. “By helping people with Parkinson’s understand how to verbalize what they are experiencing, we, as their healthcare providers, can better understand their needs and help them achieve a better sense of well-being.”

The artwork debuted on October 23 in New York at an event attended by the artists, people with Parkinson’s and their care partners. The first piece, created by Julie B., whose mom is living with Parkinson’s, is now available on LiveWellDoTell.org. Additional art pieces and stories will be revealed each month.

“Art is a powerful way to engage a community, and in Framing OFF Through Art, our goal is to create an emotional connection that results in better dialogues about Parkinson’s symptoms,” said Ron Cohen, M.D., Acorda’s President and CEO.

For more information about “Live Well. Do Tell.”, Framing OFF Through Art and to see the artwork and the stories of the individuals featured, visit LiveWellDoTell.org.

About “Live Well. Do Tell.”

“Live Well. Do Tell.” is an initiative created by Acorda with input from a multi-disciplinary steering committee of Parkinson’s community leaders. The goal of the program is to develop tools to address communication gaps among people with Parkinson’s, care partners and their healthcare professionals.

The steering committee included people with Parkinson’s, care partners, movement disorder specialists, a nurse practitioner and representatives from key advocacy groups, including the American Parkinson’s Disease Association, Caregiver Action Network, Davis Phinney Foundation, The Michael J. Fox Foundation, Parkinson’s Foundation, the Parkinson & Movement Disorder Alliance and the World Parkinson Coalition.

About Parkinson’s and OFF Periods

Parkinson’s is a progressive neurodegenerative disorder resulting from the gradual loss of certain neurons. These neurons are responsible for producing dopamine and that loss causes a range of symptoms including impaired movement, muscle stiffness and tremors. As Parkinson’s progresses, people are likely to experience OFF periods, which are characterized by the return of Parkinson’s motor and non-motor symptoms; these can occur even in the presence of regular maintenance therapy. Approximately one million people in the U.S. and 1.2 million Europeans are diagnosed with Parkinson’s; approximately 40 percent of people with Parkinson’s in the U.S. are estimated to experience OFF periods.

About Acorda Therapeutics

Founded in 1995, Acorda Therapeutics is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. Acorda has a pipeline of novel neurological therapies addressing a range of disorders, including Parkinson’s disease and multiple sclerosis. Acorda markets two FDA-approved therapies, including AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg.

Forward-Looking Statement

This press release includes forward-looking statements. All statements, other than statements of historical facts, regarding management's expectations, beliefs, goals, plans or prospects should be considered forward-looking. These statements are subject to risks and uncertainties that could cause actual results to differ materially, including: the ability to realize the benefits anticipated from acquisitions, among other reasons because acquired development programs are generally subject to all the risks inherent in the drug development process and our knowledge of the risks specifically relevant to acquired programs generally improves over time; we may need to raise additional funds to finance our operations and may not be able to do so on acceptable terms; increasing competition and accompanying loss of revenues in the U.S. from generic versions of Ampyra (dalfampridine) following our loss of patent exclusivity; the risk of unfavorable results from future studies of Inbrija (levodopa inhalation powder) or from our other research and development programs, or any other acquired or in-licensed programs; we may not be able to complete development of, obtain regulatory approval for, or successfully market Inbrija or any other products under development; risks associated with complex, regulated manufacturing processes for pharmaceuticals, which could affect whether we have sufficient commercial supply of Inbrija to meet market demand, if it receives regulatory approval; third party payers (including governmental agencies) may not reimburse for the use of Ampyra, Inbrija or our other products at acceptable rates or at all and may impose restrictive prior authorization requirements that limit or block prescriptions; the occurrence of adverse safety events with our products; the outcome (by judgment or settlement) and costs of legal, administrative or regulatory proceedings, investigations or inspections, including, without limitation, collective, representative or class action litigation; competition; failure to protect our intellectual property, to defend against the intellectual property claims of others or to obtain third party intellectual property licenses needed for the commercialization of our products; and failure to comply with regulatory requirements could result in adverse action by regulatory agencies.

These and other risks are described in greater detail in our filings with the Securities and Exchange Commission. We may not actually achieve the goals or plans described in our forward-looking statements, and investors should not place undue reliance on these statements. Forward-looking statements made in this press release are made only as of the date hereof, and we disclaim any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

Media:Tierney Saccavino(914) 326-5104tsaccavino@acorda.com

Investor Relations:Felicia Vonella(914) 326-5146fvonella@acorda.com

Latest ACOR Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.